Klein G, Wirtzfeld A, Alt E, Steck J, Saunders R, Hulse J, Kartzinel R, Lee R, Laddu A R
Int J Clin Pharmacol Ther Toxicol. 1984 Feb;22(2):112-7.
In a single-blind, placebo-controlled study, esmolol was administered intravenously to 12 patients with chronic atrial fibrillation. Esmolol produced a significant dose-dependent decrease in the ventricular rate without conversion to normal sinus rhythm in any of the patients. For most patients, a correlation was observed between the blood levels of esmolol and reductions in heart rate. There were no significant adverse effects. We conclude that esmolol is an effective and safe agent for the control of heart rate in patients with supraventricular tachycardia.
在一项单盲、安慰剂对照研究中，对12例慢性心房颤动患者静脉注射艾司洛尔。艾司洛尔使心室率出现显著的剂量依赖性降低，且所有患者均未转为正常窦性心律。对于大多数患者，观察到艾司洛尔血药浓度与心率降低之间存在相关性。未出现显著不良反应。我们得出结论，艾司洛尔是控制室上性心动过速患者心率的一种有效且安全的药物。
